Win Advisors Inc. Purchases Shares of 3,241 Amgen Inc. (NASDAQ:AMGN)

Win Advisors Inc. purchased a new stake in shares of Amgen Inc. (NASDAQ:AMGN) in the first quarter, according to the company in its most recent filing with the SEC. The fund purchased 3,241 shares of the medical research company’s stock, valued at approximately $1,010,000.

A number of other hedge funds have also added to or reduced their stakes in AMGN. Beck Mack & Oliver LLC increased its holdings in Amgen by 0.7% in the 4th quarter. Beck Mack & Oliver LLC now owns 4,623 shares of the medical research company’s stock valued at $1,205,000 after acquiring an additional 34 shares during the last quarter. Continuum Advisory LLC increased its holdings in Amgen by 0.7% in the 4th quarter. Continuum Advisory LLC now owns 5,154 shares of the medical research company’s stock valued at $1,343,000 after acquiring an additional 35 shares during the last quarter. Octavia Wealth Advisors LLC increased its holdings in Amgen by 1.5% in the 1st quarter. Octavia Wealth Advisors LLC now owns 2,435 shares of the medical research company’s stock valued at $759,000 after acquiring an additional 35 shares during the last quarter. Trillium Asset Management LLC increased its holdings in Amgen by 4.2% in the 4th quarter. Trillium Asset Management LLC now owns 911 shares of the medical research company’s stock valued at $237,000 after acquiring an additional 37 shares during the last quarter. Finally, Affinity Capital Advisors LLC increased its holdings in Amgen by 4.5% in the 1st quarter. Affinity Capital Advisors LLC now owns 861 shares of the medical research company’s stock valued at $246,000 after acquiring an additional 37 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Wall Street Analyst Weigh In

AMGN has been the topic of a number of research reports. Cantor Fitzgerald initiated coverage on shares of Amgen in a report on Tuesday, April 22nd. They issued a “neutral” rating and a $305.00 price target on the stock. UBS Group reiterated a “neutral” rating and issued a $315.00 price target (down from $319.00) on shares of Amgen in a report on Friday, May 2nd. Erste Group Bank downgraded shares of Amgen from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 8th. Royal Bank Of Canada reduced their target price on shares of Amgen from $324.00 to $320.00 and set an “outperform” rating on the stock in a report on Friday, May 2nd. Finally, Johnson Rice set a $294.00 target price on shares of Amgen in a report on Wednesday, March 5th. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating, nine have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, Amgen presently has an average rating of “Hold” and an average price target of $309.22.

Amgen Price Performance

AMGN stock opened at $272.44 on Tuesday. Amgen Inc. has a 12 month low of $253.30 and a 12 month high of $346.85. The company has a current ratio of 1.17, a quick ratio of 0.88 and a debt-to-equity ratio of 8.70. The company has a 50-day moving average price of $281.39 and a 200 day moving average price of $286.10. The stock has a market cap of $146.49 billion, a PE ratio of 24.86, a P/E/G ratio of 2.62 and a beta of 0.51.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Thursday, May 1st. The medical research company reported $4.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.18 by $0.72. The company had revenue of $8.15 billion during the quarter, compared to analysts’ expectations of $8.05 billion. Amgen had a net margin of 17.39% and a return on equity of 176.11%. The firm’s quarterly revenue was up 9.4% on a year-over-year basis. During the same period in the previous year, the company earned $3.96 EPS. Equities research analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current year.

Insider Buying and Selling at Amgen

In other Amgen news, SVP Rachna Khosla sold 1,500 shares of the business’s stock in a transaction dated Thursday, June 5th. The shares were sold at an average price of $289.68, for a total value of $434,520.00. Following the completion of the sale, the senior vice president now directly owns 8,162 shares of the company’s stock, valued at $2,364,368.16. The trade was a 15.52% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.69% of the stock is owned by corporate insiders.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.